1. Blinatumomab use in pediatric ALL: Taking a BiTE out of preparation, administration and toxicity challenges.
- Author
-
Bernhardt, Melanie B, Militano, Olga, Honeyford, Lisa, and Zupanec, Sue
- Subjects
- *
MEDICATION error prevention , *DRUG approval , *NEUROTOXICOLOGY , *SYNDROMES , *LYMPHOBLASTIC leukemia , *MONOCLONAL antibodies , *TUMORS in children , *RISK assessment , *T cells , *DRUG toxicity , *CHILDREN - Abstract
Blinatumomab is the first in its class bispecific T-cell engager monoclonal antibody, which binds to CD19 expressed on B-cells and CD3 expressed on T-cells, resulting in lysis of CD19-positive cells common in B-cell malignancies. Blinatumomab is Food and Drug Administration (FDA) approved for the treatment of adults and children with relapsed/refractory or minimal residual disease (MRD) positive precursor B-cell ALL (B-ALL). Despite impressive efficacy for the approved indications and favorable toxicity profile compared to standard-of-care chemotherapy, blinatumomab presents unique health-system challenges related to preparation, administration, toxicity monitoring and medication error prevention. Blinatumomab delivery also offers plethora of opportunities for interdisciplinary planning and collaboration. The purpose of this paper is to discuss practical considerations for safe blinatumomab delivery from the pharmacy and nursing perspectives. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF